1
|
Sheng C, Zeng Q, Huang W, Liao M, Yang P. Identification of abdominal aortic aneurysm subtypes based on mechanosensitive genes. PLoS One 2024; 19:e0296729. [PMID: 38335213 PMCID: PMC10857568 DOI: 10.1371/journal.pone.0296729] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/12/2023] [Accepted: 12/18/2023] [Indexed: 02/12/2024] Open
Abstract
BACKGROUND Rupture of abdominal aortic aneurysm (rAAA) is a fatal event in the elderly. Elevated blood pressure and weakening of vessel wall strength are major risk factors for this devastating event. This present study examined whether the expression profile of mechanosensitive genes correlates with the phenotype and outcome, thus, serving as a biomarker for AAA development. METHODS In this study, we identified mechanosensitive genes involved in AAA development using general bioinformatics methods and machine learning with six human datasets publicly available from the GEO database. Differentially expressed mechanosensitive genes (DEMGs) in AAAs were identified by differential expression analysis. Molecular biological functions of genes were explored using functional clustering, Protein-protein interaction (PPI), and weighted gene co-expression network analysis (WGCNA). According to the datasets (GSE98278, GSE205071 and GSE165470), the changes of diameter and aortic wall strength of AAA induced by DEMGs were verified by consensus clustering analysis, machine learning models, and statistical analysis. In addition, a model for identifying AAA subtypes was built using machine learning methods. RESULTS 38 DEMGs clustered in pathways regulating 'Smooth muscle cell biology' and 'Cell or Tissue connectivity'. By analyzing the GSE205071 and GSE165470 datasets, DEMGs were found to respond to differences in aneurysm diameter and vessel wall strength. Thus, in the merged datasets, we formally created subgroups of AAAs and found differences in immune characteristics between the subgroups. Finally, a model that accurately predicts the AAA subtype that is more likely to rupture was successfully developed. CONCLUSION We identified 38 DEMGs that may be involved in AAA. This gene cluster is involved in regulating the maximum vessel diameter, degree of immunoinflammatory infiltration, and strength of the local vessel wall in AAA. The prognostic model we developed can accurately identify the AAA subtypes that tend to rupture.
Collapse
Affiliation(s)
- Chang Sheng
- Department of Vascular Surgery, Xiangya Hospital, Central South University, Changsha, Hunan, China
| | - Qin Zeng
- National Health Commission Key Laboratory of Nanobiological Technology, Xiangya Hospital, Central South University, Changsha, Hunan, China
| | - Weihua Huang
- Department of Clinical Pharmacology, Hunan Key Laboratory of Pharmacogenetics, Xiangya Hospital, Central South University, Changsha, Hunan, China
- Institute of Clinical Pharmacology, Hunan Key Laboratory of Pharmacogenetics Xiangya Hospital, Central South University, Changsha, Hunan, China
- National Clinical Research Center for Geriatric Disorders, School of Pharmacy, Hunan University of Chinese Medicine, Changsha, Hunan, China
| | - Mingmei Liao
- National Health Commission Key Laboratory of Nanobiological Technology, Xiangya Hospital, Central South University, Changsha, Hunan, China
- National Clinical Research Center for Geriatric Disorders, Xiangya Hospital, Central South University, Changsha, Hunan, China
| | - Pu Yang
- Department of Vascular Surgery, Xiangya Hospital, Central South University, Changsha, Hunan, China
- National Clinical Research Center for Geriatric Disorders, Xiangya Hospital, Central South University, Changsha, Hunan, China
| |
Collapse
|
2
|
Ding M, Heydarpour M, Gomez DH, Aljaibeji H, Parksook WW, Peng L, Pojoga LH, Romero JR, Williams GH. ERAP1 Shows Distinct Regulatory Mechanisms on Blood Pressure Modulation Between Males and Females. BIORXIV : THE PREPRINT SERVER FOR BIOLOGY 2023:2023.06.07.544152. [PMID: 37333240 PMCID: PMC10274870 DOI: 10.1101/2023.06.07.544152] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 06/20/2023]
Abstract
The authors have withdrawn their manuscript owing to editing error. Therefore, the authors do not wish this work to be cited as reference for the project. If you have any questions, please contact the corresponding author.
Collapse
|
3
|
Zhang J, Yao MY, Zhang GR, Chen XR, Liu Q, Guo Y, Jia XW. Effects of different enantiomers of amlodipine on lipid profiles and vasomotor factors in atherosclerotic rabbits. Open Life Sci 2021; 16:899-908. [PMID: 34553070 PMCID: PMC8422977 DOI: 10.1515/biol-2021-0077] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/11/2020] [Revised: 06/26/2021] [Accepted: 06/29/2021] [Indexed: 11/15/2022] Open
Abstract
This research aimed to describe the functions of vascular endothelial cells (VECs) in protecting target organs and the anti-atherosclerotic effects of different enantiomers of amlodipine on a rabbit model of atherosclerosis. Thirty male New Zealand white rabbits were randomly allocated to four groups (nA = 9, nB = 7, nC = 7, and nD = 7 rabbits): rabbits in group-A (control group) were fed a high-fat diet, group-B rabbits were fed a high-fat diet plus 2.5 mg/kg/day S-amlodipine, group-C rabbits were fed a high-fat diet plus 2.5 mg/kg/day R-amlodipine, and group-D rabbits were fed a high-fat diet plus 5 mg/kg/day racemic amlodipine. Different enantiomers of amlodipine did not influence lipid profiles and serum level of eNOS in the rabbit atherosclerosis model but decreased ET-1 expression to some extent. The serum NO and iNOS levels in the drug intervention groups were significantly reduced. No significant differences in the rabbits' body weights were observed. At the 4th and 8th weeks, the serum lipid profiles significantly increased in high cholesterol diet groups. The serum ET-1 level was significantly increased in each group of rabbits at the 8th week. Both S-amlodipine and R-amlodipine may protect the endothelium by reducing the serum ET-1 level, downregulating iNOS expression.
Collapse
Affiliation(s)
- Jing Zhang
- Department of Cardiology, Affiliated Hospital of Hebei University, Baoding, Hebei, 071000, China
| | - Ming-yan Yao
- Department of Endocrinology, Baoding No. 1 Central Hospital, Baoding, Hebei, 071000, China
| | - Guo-rui Zhang
- Department of Cardiology, The Third Hospital of Shijiazhuang, Shijiazhuang, Hebei, 050000, China
| | - Xian-ru Chen
- Department of Cardiology, Affiliated Hospital of Hebei Engineering University, Handan, Hebei, 056000, China
| | - Qi Liu
- Department of Cardiology, Shijiazhuang Traditional Chinese Medicine Hospital, Shijiazhuang, Hebei, 050000, China
| | - Yifang Guo
- Cardiology Division in Geriatric Institute, Hebei Provincial People’s Hospital, Shijiazhuang, Hebei, 050000, China
| | - Xin-wei Jia
- Department of Cardiology, Affiliated Hospital of Hebei University, Baoding, Hebei, 071000, China
| |
Collapse
|
4
|
Krishna SM, Li J, Wang Y, Moran CS, Trollope A, Huynh P, Jose R, Biros E, Ma J, Golledge J. Kallistatin limits abdominal aortic aneurysm by attenuating generation of reactive oxygen species and apoptosis. Sci Rep 2021; 11:17451. [PMID: 34465809 PMCID: PMC8408144 DOI: 10.1038/s41598-021-97042-8] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/24/2021] [Accepted: 08/20/2021] [Indexed: 11/09/2022] Open
Abstract
Inflammation, vascular smooth muscle cell apoptosis and oxidative stress are believed to play important roles in abdominal aortic aneurysm (AAA) pathogenesis. Human kallistatin (KAL; gene SERPINA4) is a serine proteinase inhibitor previously shown to inhibit inflammation, apoptosis and oxidative stress. The aim of this study was to investigate the role of KAL in AAA through studies in experimental mouse models and patients. Serum KAL concentration was negatively associated with the diagnosis and growth of human AAA. Transgenic overexpression of the human KAL gene (KS-Tg) or administration of recombinant human KAL (rhKAL) inhibited AAA in the calcium phosphate (CaPO4) and subcutaneous angiotensin II (AngII) infusion mouse models. Upregulation of KAL in both models resulted in reduction in the severity of aortic elastin degradation, reduced markers of oxidative stress and less vascular smooth muscle apoptosis within the aorta. Administration of rhKAL to vascular smooth muscle cells incubated in the presence of AngII or in human AAA thrombus-conditioned media reduced apoptosis and downregulated markers of oxidative stress. These effects of KAL were associated with upregulation of Sirtuin 1 activity within the aortas of both KS-Tg mice and rodents receiving rhKAL. These results suggest KAL-Sirtuin 1 signalling limits aortic wall remodelling and aneurysm development through reductions in oxidative stress and vascular smooth muscle cell apoptosis. Upregulating KAL may be a novel therapeutic strategy for AAA.
Collapse
Affiliation(s)
- Smriti Murali Krishna
- The Vascular Biology Unit, Queensland Research Centre for Peripheral Vascular Disease, College of Medicine and Dentistry, James Cook University, Townsville, QLD, 4811, Australia
| | - Jiaze Li
- The Vascular Biology Unit, Queensland Research Centre for Peripheral Vascular Disease, College of Medicine and Dentistry, James Cook University, Townsville, QLD, 4811, Australia
| | - Yutang Wang
- The Vascular Biology Unit, Queensland Research Centre for Peripheral Vascular Disease, College of Medicine and Dentistry, James Cook University, Townsville, QLD, 4811, Australia.,School of Applied and Biomedical Sciences, Faculty of Science and Technology, Federation University Australia, Horsham, VIC, Australia
| | - Corey S Moran
- The Vascular Biology Unit, Queensland Research Centre for Peripheral Vascular Disease, College of Medicine and Dentistry, James Cook University, Townsville, QLD, 4811, Australia
| | - Alexandra Trollope
- The Vascular Biology Unit, Queensland Research Centre for Peripheral Vascular Disease, College of Medicine and Dentistry, James Cook University, Townsville, QLD, 4811, Australia.,Division of Anatomy, College of Medicine and Dentistry, James Cook University, Townsville, QLD, Australia
| | - Pacific Huynh
- The Vascular Biology Unit, Queensland Research Centre for Peripheral Vascular Disease, College of Medicine and Dentistry, James Cook University, Townsville, QLD, 4811, Australia
| | - Roby Jose
- The Vascular Biology Unit, Queensland Research Centre for Peripheral Vascular Disease, College of Medicine and Dentistry, James Cook University, Townsville, QLD, 4811, Australia
| | - Erik Biros
- The Vascular Biology Unit, Queensland Research Centre for Peripheral Vascular Disease, College of Medicine and Dentistry, James Cook University, Townsville, QLD, 4811, Australia
| | - Jianxing Ma
- Department of Physiology, Health Sciences Centre, University of Oklahoma, Oklahoma City, OK, 73104, USA
| | - Jonathan Golledge
- The Vascular Biology Unit, Queensland Research Centre for Peripheral Vascular Disease, College of Medicine and Dentistry, James Cook University, Townsville, QLD, 4811, Australia. .,Department of Vascular and Endovascular Surgery, Townsville University Hospital, Townsville, QLD, Australia.
| |
Collapse
|
5
|
Cooper HA, Cicalese S, Preston KJ, Kawai T, Okuno K, Choi ET, Kasahara S, Uchida HA, Otaka N, Scalia R, Rizzo V, Eguchi S. Targeting mitochondrial fission as a potential therapeutic for abdominal aortic aneurysm. Cardiovasc Res 2021; 117:971-982. [PMID: 32384150 PMCID: PMC7898955 DOI: 10.1093/cvr/cvaa133] [Citation(s) in RCA: 53] [Impact Index Per Article: 17.7] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 11/27/2019] [Revised: 04/15/2020] [Accepted: 04/30/2020] [Indexed: 11/12/2022] Open
Abstract
AIMS Angiotensin II (AngII) is a potential contributor to the development of abdominal aortic aneurysm (AAA). In aortic vascular smooth muscle cells (VSMCs), exposure to AngII induces mitochondrial fission via dynamin-related protein 1 (Drp1). However, pathophysiological relevance of mitochondrial morphology in AngII-associated AAA remains unexplored. Here, we tested the hypothesis that mitochondrial fission is involved in the development of AAA. METHODS AND RESULTS Immunohistochemistry was performed on human AAA samples and revealed enhanced expression of Drp1. In C57BL6 mice treated with AngII plus β-aminopropionitrile, AAA tissue also showed an increase in Drp1 expression. A mitochondrial fission inhibitor, mdivi1, attenuated AAA size, associated aortic pathology, Drp1 protein induction, and mitochondrial fission but not hypertension in these mice. Moreover, western-blot analysis showed that induction of matrix metalloproteinase-2, which precedes the development of AAA, was blocked by mdivi1. Mdivi1 also reduced the development of AAA in apolipoprotein E-deficient mice infused with AngII. As with mdivi1, Drp1+/- mice treated with AngII plus β-aminopropionitrile showed a decrease in AAA compared to control Drp1+/+ mice. In abdominal aortic VSMCs, AngII induced phosphorylation of Drp1 and mitochondrial fission, the latter of which was attenuated with Drp1 silencing as well as mdivi1. AngII also induced vascular cell adhesion molecule-1 expression and enhanced leucocyte adhesion and mitochondrial oxygen consumption in smooth muscle cells, which were attenuated with mdivi1. CONCLUSION These data indicate that Drp1 and mitochondrial fission play salient roles in AAA development, which likely involves mitochondrial dysfunction and inflammatory activation of VSMCs.
Collapse
MESH Headings
- Aminopropionitrile
- Angiotensin II
- Animals
- Anti-Inflammatory Agents/pharmacology
- Aorta, Abdominal/drug effects
- Aorta, Abdominal/metabolism
- Aorta, Abdominal/pathology
- Aortic Aneurysm, Abdominal/chemically induced
- Aortic Aneurysm, Abdominal/metabolism
- Aortic Aneurysm, Abdominal/pathology
- Aortic Aneurysm, Abdominal/prevention & control
- Case-Control Studies
- Cell Adhesion/drug effects
- Cells, Cultured
- Disease Models, Animal
- Dynamins/genetics
- Dynamins/metabolism
- Humans
- Leukocytes/drug effects
- Leukocytes/metabolism
- Male
- Mice, Inbred C57BL
- Mice, Knockout, ApoE
- Mitochondria, Muscle/drug effects
- Mitochondria, Muscle/genetics
- Mitochondria, Muscle/metabolism
- Mitochondria, Muscle/pathology
- Mitochondrial Dynamics/drug effects
- Muscle, Smooth, Vascular/drug effects
- Muscle, Smooth, Vascular/metabolism
- Muscle, Smooth, Vascular/pathology
- Myocytes, Smooth Muscle/drug effects
- Myocytes, Smooth Muscle/metabolism
- Myocytes, Smooth Muscle/pathology
- Oxygen Consumption/drug effects
- Phosphorylation
- Quinazolinones/pharmacology
- Mice
Collapse
Affiliation(s)
- Hannah A Cooper
- Cardiovascular Research Center, Lewis Katz School of Medicine, Temple University, Philadelphia, PA 19140, USA
| | - Stephanie Cicalese
- Cardiovascular Research Center, Lewis Katz School of Medicine, Temple University, Philadelphia, PA 19140, USA
| | - Kyle J Preston
- Cardiovascular Research Center, Lewis Katz School of Medicine, Temple University, Philadelphia, PA 19140, USA
| | - Tatsuo Kawai
- Cardiovascular Research Center, Lewis Katz School of Medicine, Temple University, Philadelphia, PA 19140, USA
| | - Keisuke Okuno
- Cardiovascular Research Center, Lewis Katz School of Medicine, Temple University, Philadelphia, PA 19140, USA
| | - Eric T Choi
- Department of Surgery, Lewis Katz School of Medicine, Temple University, Philadelphia, PA 19140, USA
| | - Shingo Kasahara
- Department of Cardiovascular Surgery, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, Okayama 700-8558, Japan
| | - Haruhito A Uchida
- Department of Chronic Kidney Disease and Cardiovascular Disease, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, Okayama 700-8558, Japan
| | - Nozomu Otaka
- Department of Nephrology, Rheumatology, Endocrinology and Metabolism, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, Okayama 700-8558, Japan
| | - Rosario Scalia
- Cardiovascular Research Center, Lewis Katz School of Medicine, Temple University, Philadelphia, PA 19140, USA
| | - Victor Rizzo
- Cardiovascular Research Center, Lewis Katz School of Medicine, Temple University, Philadelphia, PA 19140, USA
| | - Satoru Eguchi
- Cardiovascular Research Center, Lewis Katz School of Medicine, Temple University, Philadelphia, PA 19140, USA
| |
Collapse
|
6
|
Matrix Metalloproteinase in Abdominal Aortic Aneurysm and Aortic Dissection. Pharmaceuticals (Basel) 2019; 12:ph12030118. [PMID: 31390798 PMCID: PMC6789891 DOI: 10.3390/ph12030118] [Citation(s) in RCA: 98] [Impact Index Per Article: 19.6] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/14/2019] [Revised: 07/25/2019] [Accepted: 08/02/2019] [Indexed: 12/12/2022] Open
Abstract
Abdominal Aortic Aneurysm (AAA) affects 4–5% of men over 65, and Aortic Dissection (AD) is a life-threatening aortic pathology associated with high morbidity and mortality. Initiators of AAA and AD include smoking and arterial hypertension, whilst key pathophysiological features of AAA and AD include chronic inflammation, hypoxia, and large modifications to the extra cellular matrix (ECM). As it stands, only surgical methods are available for preventing aortic rupture in patients, which often presents difficulties for recovery. No pharmacological treatment is available, as such researchers are attempting to understand the cellular and molecular pathophysiology of AAA and AD. Upregulation of matrix metalloproteinase (MMPs), particularly MMP-2 and MMP-9, has been identified as a key event occurring during aneurysmal growth. As such, several animal models of AAA and AD have been used to investigate the therapeutic potential of suppressing MMP-2 and MMP-9 activity as well as modulating the activity of other MMPs, and TIMPs involved in the pathology. Whilst several studies have offered promising results, targeted delivery of MMP inhibition still needs to be developed in order to avoid surgery in high risk patients.
Collapse
|
7
|
The effects of anti-hypertensive drugs and the mechanism of hypertension in vascular smooth muscle cell-specific ATP2B1 knockout mice. Hypertens Res 2017; 41:80-87. [PMID: 29046519 PMCID: PMC5811637 DOI: 10.1038/hr.2017.92] [Citation(s) in RCA: 15] [Impact Index Per Article: 2.1] [Reference Citation Analysis] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/03/2017] [Revised: 06/21/2017] [Accepted: 07/27/2017] [Indexed: 01/11/2023]
Abstract
ATP2B1 is a gene associated with hypertension. We reported previously that mice lacking ATP2B1 in vascular smooth muscle cells (VSMC ATP2B1 KO mice) exhibited high blood pressure and increased intracellular calcium concentration. The present study was designed to investigate whether lack of the ATP2B1 gene causes a higher response to calcium channel blockers (CCBs) than to other types of anti-hypertensive drugs. Both VSMC ATP2B1 KO and control mice were administered anti-hypertensive drugs while monitoring blood pressure shifts. We also examined the association of nitric oxide synthase (NOS) activity in those mice to investigate whether another mechanism of hypertension existed. VSMC ATP2B1 KO mice exhibited significantly greater anti-hypertensive effects with a single injection of nicardipine, but the effects of an angiotensin II receptor blocker (ARB), an α-blocker and amlodipine on blood pressure were all similar to control mice. However, long-term treatment with amlodipine, but not an ARB, significantly decreased the blood pressure of KO mice compared with control mice. Both mRNA and protein expression levels of the L-type calcium channel were significantly upregulated in KO VSMCs. There were no alterations in neural NOS protein expression of VSMCs or in urinary NO production between the two groups. VSMC ATP2B1 KO mice had a higher response to CCBs for blood pressure-lowering effects than other anti-hypertensive drugs. These results mean that increased intracellular calcium concentration in VSMCs due to lack of ATP2B1 and subsequent activation of L-type calcium channels mainly affects blood pressure and suggests increased susceptibility to CCBs in this type of hypertension.
Collapse
|
8
|
Hu HJ, Jiang ZS, Zhou SH, Liu QM. Hydrogen sulfide suppresses angiotensin II-stimulated endothelin-1 generation and subsequent cytotoxicity-induced endoplasmic reticulum stress in endothelial cells via NF-κB. Mol Med Rep 2016; 14:4729-4740. [DOI: 10.3892/mmr.2016.5827] [Citation(s) in RCA: 12] [Impact Index Per Article: 1.5] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/12/2015] [Accepted: 08/09/2016] [Indexed: 11/06/2022] Open
|
9
|
Trachet B, Piersigilli A, Fraga-Silva RA, Aslanidou L, Sordet-Dessimoz J, Astolfo A, Stampanoni MFM, Segers P, Stergiopulos N. Ascending Aortic Aneurysm in Angiotensin II-Infused Mice: Formation, Progression, and the Role of Focal Dissections. Arterioscler Thromb Vasc Biol 2016; 36:673-81. [PMID: 26891740 DOI: 10.1161/atvbaha.116.307211] [Citation(s) in RCA: 58] [Impact Index Per Article: 7.3] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/14/2015] [Accepted: 02/05/2016] [Indexed: 11/16/2022]
Abstract
OBJECTIVE To understand the anatomy and physiology of ascending aortic aneurysms in angiotensin II-infused ApoE(-/-) mice. APPROACH AND RESULTS We combined an extensive in vivo imaging protocol (high-frequency ultrasound and contrast-enhanced microcomputed tomography at baseline and after 3, 10, 18, and 28 days of angiotensin II infusion) with synchrotron-based ultrahigh resolution ex vivo imaging (phase contrast X-ray tomographic microscopy) in n=47 angiotensin II-infused mice and 6 controls. Aortic regurgitation increased significantly over time, as did the luminal volume of the ascending aorta. In the samples that were scanned ex vivo, we observed one or several focal dissections, with the largest located in the outer convex aspect of the ascending aorta. The volume of the dissections moderately correlated to the volume of the aneurysm as measured in vivo (r(2)=0.46). After 3 days of angiotensin II infusion, we found an interlaminar hematoma in 7/12 animals, which could be linked to an intimal tear. There was also a significant increase in single laminar ruptures, which may have facilitated a progressive enlargement of the focal dissections over time. At later time points, the hematoma was resorbed and the medial and adventitial thickness increased. Fatal transmural dissection occurred in 8/47 mice at an early stage of the disease, before adventita remodeling. CONCLUSIONS We visualized and quantified the dissections that lead to ascending aortic aneurysms in angiotensin II-infused mice and provided unique insight into the temporal evolution of these lesions.
Collapse
Affiliation(s)
- Bram Trachet
- From the Institute of Bioengineering, Ecole Polytechnique Fédérale de Lausanne, Lausanne, Switzerland (B.T., R.A.F.-S., L.A., N.S.); IBiTech-bioMMeda, Ghent University-iMinds Medical IT, Ghent, Belgium (B.T., P.S.); School of Life Sciences, PTEC GE, Ecole Polytechnique Fédérale de Lausanne, Lausanne, Switzerland (A.P.); Institute of Animal Pathology, Vetsuisse Faculty, University of Bern, Bern, Switzerland (A.P.); Histology Core Facility, Ecole Polytechnique Fédérale de Lausanne, Lausanne, Switzerland (J.S.-D.); Swiss Light Source, Paul Scherrer Institut, Villigen, Switzerland (A.A., M.F.M.S.); and Institute for Biomedical Engineering, University and ETH Zürich, Zürich, Switzerland (M.F.M.S.).
| | - Alessandra Piersigilli
- From the Institute of Bioengineering, Ecole Polytechnique Fédérale de Lausanne, Lausanne, Switzerland (B.T., R.A.F.-S., L.A., N.S.); IBiTech-bioMMeda, Ghent University-iMinds Medical IT, Ghent, Belgium (B.T., P.S.); School of Life Sciences, PTEC GE, Ecole Polytechnique Fédérale de Lausanne, Lausanne, Switzerland (A.P.); Institute of Animal Pathology, Vetsuisse Faculty, University of Bern, Bern, Switzerland (A.P.); Histology Core Facility, Ecole Polytechnique Fédérale de Lausanne, Lausanne, Switzerland (J.S.-D.); Swiss Light Source, Paul Scherrer Institut, Villigen, Switzerland (A.A., M.F.M.S.); and Institute for Biomedical Engineering, University and ETH Zürich, Zürich, Switzerland (M.F.M.S.)
| | - Rodrigo A Fraga-Silva
- From the Institute of Bioengineering, Ecole Polytechnique Fédérale de Lausanne, Lausanne, Switzerland (B.T., R.A.F.-S., L.A., N.S.); IBiTech-bioMMeda, Ghent University-iMinds Medical IT, Ghent, Belgium (B.T., P.S.); School of Life Sciences, PTEC GE, Ecole Polytechnique Fédérale de Lausanne, Lausanne, Switzerland (A.P.); Institute of Animal Pathology, Vetsuisse Faculty, University of Bern, Bern, Switzerland (A.P.); Histology Core Facility, Ecole Polytechnique Fédérale de Lausanne, Lausanne, Switzerland (J.S.-D.); Swiss Light Source, Paul Scherrer Institut, Villigen, Switzerland (A.A., M.F.M.S.); and Institute for Biomedical Engineering, University and ETH Zürich, Zürich, Switzerland (M.F.M.S.)
| | - Lydia Aslanidou
- From the Institute of Bioengineering, Ecole Polytechnique Fédérale de Lausanne, Lausanne, Switzerland (B.T., R.A.F.-S., L.A., N.S.); IBiTech-bioMMeda, Ghent University-iMinds Medical IT, Ghent, Belgium (B.T., P.S.); School of Life Sciences, PTEC GE, Ecole Polytechnique Fédérale de Lausanne, Lausanne, Switzerland (A.P.); Institute of Animal Pathology, Vetsuisse Faculty, University of Bern, Bern, Switzerland (A.P.); Histology Core Facility, Ecole Polytechnique Fédérale de Lausanne, Lausanne, Switzerland (J.S.-D.); Swiss Light Source, Paul Scherrer Institut, Villigen, Switzerland (A.A., M.F.M.S.); and Institute for Biomedical Engineering, University and ETH Zürich, Zürich, Switzerland (M.F.M.S.)
| | - Jessica Sordet-Dessimoz
- From the Institute of Bioengineering, Ecole Polytechnique Fédérale de Lausanne, Lausanne, Switzerland (B.T., R.A.F.-S., L.A., N.S.); IBiTech-bioMMeda, Ghent University-iMinds Medical IT, Ghent, Belgium (B.T., P.S.); School of Life Sciences, PTEC GE, Ecole Polytechnique Fédérale de Lausanne, Lausanne, Switzerland (A.P.); Institute of Animal Pathology, Vetsuisse Faculty, University of Bern, Bern, Switzerland (A.P.); Histology Core Facility, Ecole Polytechnique Fédérale de Lausanne, Lausanne, Switzerland (J.S.-D.); Swiss Light Source, Paul Scherrer Institut, Villigen, Switzerland (A.A., M.F.M.S.); and Institute for Biomedical Engineering, University and ETH Zürich, Zürich, Switzerland (M.F.M.S.)
| | - Alberto Astolfo
- From the Institute of Bioengineering, Ecole Polytechnique Fédérale de Lausanne, Lausanne, Switzerland (B.T., R.A.F.-S., L.A., N.S.); IBiTech-bioMMeda, Ghent University-iMinds Medical IT, Ghent, Belgium (B.T., P.S.); School of Life Sciences, PTEC GE, Ecole Polytechnique Fédérale de Lausanne, Lausanne, Switzerland (A.P.); Institute of Animal Pathology, Vetsuisse Faculty, University of Bern, Bern, Switzerland (A.P.); Histology Core Facility, Ecole Polytechnique Fédérale de Lausanne, Lausanne, Switzerland (J.S.-D.); Swiss Light Source, Paul Scherrer Institut, Villigen, Switzerland (A.A., M.F.M.S.); and Institute for Biomedical Engineering, University and ETH Zürich, Zürich, Switzerland (M.F.M.S.)
| | - Marco F M Stampanoni
- From the Institute of Bioengineering, Ecole Polytechnique Fédérale de Lausanne, Lausanne, Switzerland (B.T., R.A.F.-S., L.A., N.S.); IBiTech-bioMMeda, Ghent University-iMinds Medical IT, Ghent, Belgium (B.T., P.S.); School of Life Sciences, PTEC GE, Ecole Polytechnique Fédérale de Lausanne, Lausanne, Switzerland (A.P.); Institute of Animal Pathology, Vetsuisse Faculty, University of Bern, Bern, Switzerland (A.P.); Histology Core Facility, Ecole Polytechnique Fédérale de Lausanne, Lausanne, Switzerland (J.S.-D.); Swiss Light Source, Paul Scherrer Institut, Villigen, Switzerland (A.A., M.F.M.S.); and Institute for Biomedical Engineering, University and ETH Zürich, Zürich, Switzerland (M.F.M.S.)
| | - Patrick Segers
- From the Institute of Bioengineering, Ecole Polytechnique Fédérale de Lausanne, Lausanne, Switzerland (B.T., R.A.F.-S., L.A., N.S.); IBiTech-bioMMeda, Ghent University-iMinds Medical IT, Ghent, Belgium (B.T., P.S.); School of Life Sciences, PTEC GE, Ecole Polytechnique Fédérale de Lausanne, Lausanne, Switzerland (A.P.); Institute of Animal Pathology, Vetsuisse Faculty, University of Bern, Bern, Switzerland (A.P.); Histology Core Facility, Ecole Polytechnique Fédérale de Lausanne, Lausanne, Switzerland (J.S.-D.); Swiss Light Source, Paul Scherrer Institut, Villigen, Switzerland (A.A., M.F.M.S.); and Institute for Biomedical Engineering, University and ETH Zürich, Zürich, Switzerland (M.F.M.S.)
| | - Nikolaos Stergiopulos
- From the Institute of Bioengineering, Ecole Polytechnique Fédérale de Lausanne, Lausanne, Switzerland (B.T., R.A.F.-S., L.A., N.S.); IBiTech-bioMMeda, Ghent University-iMinds Medical IT, Ghent, Belgium (B.T., P.S.); School of Life Sciences, PTEC GE, Ecole Polytechnique Fédérale de Lausanne, Lausanne, Switzerland (A.P.); Institute of Animal Pathology, Vetsuisse Faculty, University of Bern, Bern, Switzerland (A.P.); Histology Core Facility, Ecole Polytechnique Fédérale de Lausanne, Lausanne, Switzerland (J.S.-D.); Swiss Light Source, Paul Scherrer Institut, Villigen, Switzerland (A.A., M.F.M.S.); and Institute for Biomedical Engineering, University and ETH Zürich, Zürich, Switzerland (M.F.M.S.)
| |
Collapse
|
10
|
Doyle JJ, Doyle AJ, Wilson NK, Habashi JP, Bedja D, Whitworth RE, Lindsay ME, Schoenhoff F, Myers L, Huso N, Bachir S, Squires O, Rusholme B, Ehsan H, Huso D, Thomas CJ, Caulfield MJ, Van Eyk JE, Judge DP, Dietz HC. A deleterious gene-by-environment interaction imposed by calcium channel blockers in Marfan syndrome. eLife 2015; 4. [PMID: 26506064 PMCID: PMC4621743 DOI: 10.7554/elife.08648] [Citation(s) in RCA: 62] [Impact Index Per Article: 6.9] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/11/2015] [Accepted: 09/22/2015] [Indexed: 01/01/2023] Open
Abstract
Calcium channel blockers (CCBs) are prescribed to patients with Marfan syndrome for prophylaxis against aortic aneurysm progression, despite limited evidence for their efficacy and safety in the disorder. Unexpectedly, Marfan mice treated with CCBs show accelerated aneurysm expansion, rupture, and premature lethality. This effect is both extracellular signal-regulated kinase (ERK1/2) dependent and angiotensin-II type 1 receptor (AT1R) dependent. We have identified protein kinase C beta (PKCβ) as a critical mediator of this pathway and demonstrate that the PKCβ inhibitor enzastaurin, and the clinically available anti-hypertensive agent hydralazine, both normalize aortic growth in Marfan mice, in association with reduced PKCβ and ERK1/2 activation. Furthermore, patients with Marfan syndrome and other forms of inherited thoracic aortic aneurysm taking CCBs display increased risk of aortic dissection and need for aortic surgery, compared to patients on other antihypertensive agents. DOI:http://dx.doi.org/10.7554/eLife.08648.001 Marfan syndrome is a disorder that affects the body's connective tissues, which maintain the structure of the body and support organs and other tissues. People with Marfan syndrome have connective tissues that can stretch more than those of other people, which put them at increased risk of a life-threatening tear in their aorta (the main artery in the body), muscle weakness and other problems. A cell communication pathway called TGFβ signaling is involved in cell growth and many other important processes. TGFβ signaling is more active in patients with Marfan syndrome due to mutations in a gene called FBN1. Drugs that block TGFβ signaling—which are also used to treat high blood pressure—can reduce the symptoms of the disorder. Unfortunately, not all people with Marfan disease can tolerate these drugs and other medications called calcium channel blockers, which also lower blood pressure, are often used as an alternative. It is thought that calcium channel blockers help reduce stress on blood vessels, but there is little data to show whether these drugs are safe and helpful for patients with Marfan syndrome. Now, Doyle, Doyle et al. studied the effect of two different calcium channel blockers on mice that have a mutation in Fbn1—the mouse equivalent of FBN1—that is similar to those found in humans with Marfan syndrome. The experiments show that the aortas of these mice grew more quickly and were more likely to tear when compared to mice that did not receive these drugs. Many of these aortic tears were fatal. The calcium channel blockers increased the activity of two signaling molecules that are regulated by TGFβ signaling. Treating the Marfan mice with other drugs that lower the activity of these signaling molecules protected the aorta, even if they were also treated with the calcium channel blockers. Doyle, Doyle et al. examined a registry of human patients. This revealed preliminary evidence that aortic tears and aortic repair surgery were more common in patients with Marfan syndrome who had received calcium channel blockers than patients who had been treated with other drugs. Together, these findings suggest that it may be dangerous to treat patients with Marfan syndrome with calcium channel blockers. Additional work will be needed to confirm this risk, to find out if it extends to other similar conditions, and to explore the therapeutic potential of drugs that target the two enzymes. DOI:http://dx.doi.org/10.7554/eLife.08648.002
Collapse
Affiliation(s)
- Jefferson J Doyle
- Howard Hughes Medical Institute and Institute of Genetic Medicine, Johns Hopkins University School of Medicine, Baltimore, United States.,Wilmer Eye Institute, Johns Hopkins University School of Medicine, Baltimore, United States
| | - Alexander J Doyle
- Howard Hughes Medical Institute and Institute of Genetic Medicine, Johns Hopkins University School of Medicine, Baltimore, United States.,William Harvey Research Institute, Barts and The London School of Medicine, Queen Mary University of London, London, United Kingdom
| | - Nicole K Wilson
- Howard Hughes Medical Institute and Institute of Genetic Medicine, Johns Hopkins University School of Medicine, Baltimore, United States
| | - Jennifer P Habashi
- Howard Hughes Medical Institute and Institute of Genetic Medicine, Johns Hopkins University School of Medicine, Baltimore, United States.,Division of Pediatric Cardiology, Department of Pediatrics, Johns Hopkins University School of Medicine, Baltimore, United States
| | - Djahida Bedja
- Department of Cardiology, Johns Hopkins University School of Medicine, Baltimore, United States.,Australian School of Advanced Medicine, Macquarie University, Sydney, Australia
| | - Ryan E Whitworth
- Research Triangle Institute International, Durham, United States
| | - Mark E Lindsay
- Thoracic Aortic Center, Departments of Medicine and Pediatrics, Massachusetts General Hospital, Harvard Medical School, Boston, United States
| | - Florian Schoenhoff
- Department of Cardiovascular Surgery, Inselspital, Bern, Switzerland.,Proteomics Innovation Center in Heart Failure, Johns Hopkins University School of Medicine, Baltimore, United States
| | - Loretha Myers
- Howard Hughes Medical Institute and Institute of Genetic Medicine, Johns Hopkins University School of Medicine, Baltimore, United States
| | - Nick Huso
- Howard Hughes Medical Institute and Institute of Genetic Medicine, Johns Hopkins University School of Medicine, Baltimore, United States
| | - Suha Bachir
- Howard Hughes Medical Institute and Institute of Genetic Medicine, Johns Hopkins University School of Medicine, Baltimore, United States
| | - Oliver Squires
- Howard Hughes Medical Institute and Institute of Genetic Medicine, Johns Hopkins University School of Medicine, Baltimore, United States
| | - Benjamin Rusholme
- Howard Hughes Medical Institute and Institute of Genetic Medicine, Johns Hopkins University School of Medicine, Baltimore, United States
| | - Hamid Ehsan
- Wilmer Eye Institute, Johns Hopkins University School of Medicine, Baltimore, United States
| | - David Huso
- Department of Molecular and Comparative Pathobiology, Johns Hopkins University School of Medicine, Baltimore, United States
| | - Craig J Thomas
- Division of Preclinical Innovation, National Center for Advancing Translational Sciences, Bethesda, United States
| | - Mark J Caulfield
- William Harvey Research Institute, Barts and The London School of Medicine, Queen Mary University of London, London, United Kingdom
| | - Jennifer E Van Eyk
- Proteomics Innovation Center in Heart Failure, Johns Hopkins University School of Medicine, Baltimore, United States
| | - Daniel P Judge
- Department of Medicine, Johns Hopkins University School of Medicine, Baltimore, United States
| | - Harry C Dietz
- Howard Hughes Medical Institute and Institute of Genetic Medicine, Johns Hopkins University School of Medicine, Baltimore, United States.,Division of Pediatric Cardiology, Department of Pediatrics, Johns Hopkins University School of Medicine, Baltimore, United States.,Department of Medicine, Johns Hopkins University School of Medicine, Baltimore, United States
| | | | | |
Collapse
|
11
|
Miao XN, Siu KL, Cai H. Nifedipine attenuation of abdominal aortic aneurysm in hypertensive and non-hypertensive mice: Mechanisms and implications. J Mol Cell Cardiol 2015; 87:152-9. [PMID: 26254182 DOI: 10.1016/j.yjmcc.2015.07.031] [Citation(s) in RCA: 26] [Impact Index Per Article: 2.9] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 02/20/2015] [Revised: 07/28/2015] [Accepted: 07/30/2015] [Indexed: 02/07/2023]
Abstract
Rupture of abdominal aortic aneurysm (AAA) is a lethal event. No oral medicine has been available to prevent or treat AAA. We have recently identified a novel mechanism of eNOS uncoupling by which AAA develops, in angiotensin II (Ang II) infused hyperphenylalaninemia 1 (hph-1) mice. Using this unique model we investigated effects on AAA formation of the L-type calcium channel blocker nifedipine, in view of the unclear relationship between hypertension and AAA, and unclear mechanisms of aneurysm protective effects of some blood pressure lowering drugs. Six-month old hph-1 mice were infused with Ang II (0.7 mg/kg/day) for 2 weeks, and fed nifedipine chow at two different doses (5 and 20 mg/kg/day). While the high dose of nifedipine reduced blood pressure, the lower dose had no effect. Interestingly, the incidence rate of AAA dropped from 71% to 7 and 12.5% for low and high dose nifedipine, respectively. Expansion of abdominal aorta, determined by ultrasound imaging, was abolished by both doses of nifedipine, which recoupled eNOS completely to improve NO bioavailability. Both also abrogated aortic superoxide production. Of note, Ang II activation of NADPH oxidase in vascular smooth muscle cells and endothelial cells, known to uncouple eNOS, was also attenuated by nifedipine. Although low dose was a sub-pressor while the high dose reduced blood pressure via inhibition of calcium channels, both doses were highly effective in preventing AAA by preserving eNOS coupling activity to eliminate sustained oxidative stress from uncoupled eNOS. These data demonstrate that oral treatment of nifedipine is highly effective in preserving eNOS function to attenuate AAA formation. Nifedipine may be used for AAA prevention either at low dose in AAA risk group, or at high dose in patients with co-existing hypertension.
Collapse
Affiliation(s)
- Xiao Niu Miao
- Divisions of Molecular Medicine and Cardiology, Departments of Anesthesiology and Medicine, Cardiovascular Research Laboratories, David Geffen School of Medicine, University of California Los Angeles, Los Angeles, CA 90025, USA; School of Life Science and Technology, China Pharmaceutical University, Nanjing 210009, PR China
| | - Kin Lung Siu
- Divisions of Molecular Medicine and Cardiology, Departments of Anesthesiology and Medicine, Cardiovascular Research Laboratories, David Geffen School of Medicine, University of California Los Angeles, Los Angeles, CA 90025, USA
| | - Hua Cai
- Divisions of Molecular Medicine and Cardiology, Departments of Anesthesiology and Medicine, Cardiovascular Research Laboratories, David Geffen School of Medicine, University of California Los Angeles, Los Angeles, CA 90025, USA.
| |
Collapse
|